NAGE Q3 2020 Earnings — Niagen Bioscience Inc Revenue & Financial Results | Market Cap Arena

NAGENiagen Bioscience Inc

$393M

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M+17.6% YoY

Gross Profit

$8M59.6% margin

Operating Income

-$4M-29.6% margin

Net Income

-$4M-29.7% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

-7.2%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$37M

Total Liabilities

$18M

Stockholders' Equity

$19M

Cash & Equivalents

$15M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$12M	+17.6%
Gross Profit	$8M	$7M	+25.3%
Operating Income	-$4M	-$7M	+39.1%
Net Income	-$4M	-$7M	+41.5%